PBS updates

Zydelig (Idelalisib)

idelalisib 100 mg tablet, 60 · ORAL · PBS code 11171Y

AUTHORITY_REQUIRED

What it costs

AU$4956.86 PBS-determined price per 60 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2017-09-01.
  • • Repeats: 5.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Refractory follicular B-cell non-Hodgkin's lymphoma


Initial treatment


The condition must be refractory to a prior therapy with rituximab within 6 months after completion of treatment with rituximab; AND

The condition must be refractory to a prior therapy with an alkylating agent within 6 months after completion of treatment with an alkylating agent; AND

The treatment must be the sole PBS-subsidised therapy for this condition.

The condition is considered refractory to a prior therapy when the patient experiences less than a partial response or progression of disease within 6 months after completion of the prior therapy.

The condition is considered refractory to both rituximab and an alkylating agent if the agents were administered together or in successive treatment regimens.

The date of completion of prior therapies with rituximab and an alkylating agent must be documented in the patient's medical records.

Sponsor: Gilead Sciences Pty Limited ABN 71 072 611 708

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.